IDEAYA Biosciences

IDEAYA Biosciences unveiled its 2026 strategic roadmap, focusing on advancing its pipeline. Key objectives include presenting darovasertib trial results for uveal melanoma, potentially supporting accelerated approval, and initiating four registrational trials. The company will also advance its antibody-drug conjugate programs, including IDE849 for neuroendocrine cancers, and explore next-generation therapies targeting MTAP pathway alterations and CDKN2A. With substantial cash reserves extending into 2030, IDEAYA is set for significant pipeline progress and potential regulatory milestones.

IDEAYA Biosciences announced stock option grants to a new employee. The company awarded 95,600 shares at $22.29 per share under its 2023 plan, aiming to attract talent. Options vest over four years, with 25% vesting after the first year. IDEAYA, a precision medicine oncology company, focuses on targeted therapies based on molecular diagnostics and synthetic lethality approaches.